# Morgan Stanley Emerging Markets Debt Fund (MSD) — News MSD · NYSE · Stock Canonical page: https://www.lighthorse.io/tickers/msd/news ## Recent headlines - [Shares of US chip-related companies fall](https://www.ainvest.com/news/shares-chip-related-companies-fall-2610) — AInvest Wire, Oct 13, 2026 Shares of US chip-related companies fell sharply on Tuesday, contributing to a broader decline in the Nasdaq and S&P 500 indices. The semiconductor sector, which has experienced a significant rally this year, saw a pullback as investors took profits following months of strong gains. Micron, AMD,… - [Merck showcases first-time pivotal phase 3 results from oncology pipeline and continued innovative potential of existing portfolio at ESMO 2026](https://www.ainvest.com/news/merck-showcases-time-pivotal-phase-3-results-oncology-pipeline-continued-innovative-potential-existing-portfolio-esmo-2026-2610) — AInvest Wire, Oct 13, 2026 Merck (MSD outside the U.S. and Canada) is set to present first-time pivotal Phase 3 results from its oncology pipeline at the European Society for Medical Oncology (ESMO) Congress 2026, scheduled for October 17–21 in Berlin, Germany. The data will cover more than 100 abstracts across over 20… - [MRC/UVRI & LSHTM Uganda research unit - Uganda launches phase I clinical study of Bundibugyo virus disease vaccine](https://www.ainvest.com/news/mrc-uvri-lshtm-uganda-research-unit-uganda-launches-phase-clinical-study-bundibugyo-virus-disease-vaccine-2610) — AInvest Wire, Oct 6, 2026 The MRC/UVRI & LSHTM Uganda Research Unit has initiated a phase I clinical trial for a Bundibugyo virus disease vaccine, marking a significant step in the global response to the ongoing outbreak. This development follows a collaborative effort between CEPI and Hilleman Laboratories, a joint venture… - [MSD says subcutaneous formulation of PD-1 inhibitor pembrolizumab approved in China - Statement](https://www.ainvest.com/news/msd-subcutaneous-formulation-pd-1-inhibitor-pembrolizumab-approved-china-statement-2609) — AInvest Wire, Sep 29, 2026 Merck & Co. (NYSE: MRK), through its global brand MSD, announced that the subcutaneous formulation of pembrolizumab, marketed as Keytruda in the United States and under the MSD brand in other regions, has received regulatory approval in China. The subcutaneous formulation offers an alternative… - [Fitch affirms MSD investment at 'BBB-'; outlook stable](https://www.ainvest.com/news/fitch-affirms-msd-investment-bbb-outlook-stable-2606) — AInvest Wire, Jun 22, 2026 Fitch Ratings has affirmed the credit rating of MSD Investment Corp. at 'BBB-', with a stable outlook, reflecting the company’s strong credit fundamentals and diversified investment portfolio. The rating agency highlighted MSD’s $4.9 billion investment portfolio, which is predominantly composed of… --- Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express. This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness. Data provided by [AInvest](https://www.ainvest.com).